Folic acid and Reblozyl drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Folic acid and Reblozyl. Common interactions include fatigue among males.

The phase IV clinical study analyzes what interactions people who take Folic acid and Reblozyl have. It is created by eHealthMe based on reports of 10 people who take Folic acid and Reblozyl from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Nov, 30, 2022

10 people who take Folic acid and Reblozyl together, and have interactions are studied.


What is Folic acid?

Folic acid has active ingredients of folic acid. It is often used in rheumatoid arthritis. eHealthMe is studying from 124,951 Folic acid users for its effectiveness, alternative drugs and more.

What is Reblozyl?

Reblozyl has active ingredients of luspatercept-aamt. eHealthMe is studying from 556 Reblozyl users for its effectiveness, alternative drugs and more.

Number of Folic acid and Reblozyl reports submitted per year:

Folic acid and Reblozyl drug interactions.

Common Folic Acid and Reblozyl drug interactions by gender *:

female:

n/a

male:

  1. Fatigue
  2. Hepatic cirrhosis
  3. Hypotension
  4. Memory impairment
  5. Oedema peripheral
  6. Pain
  7. Pneumonia
  8. Pyrexia
  9. Renal impairment
  10. Respiratory tract infection

Common Folic Acid and Reblozyl drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Ammonia increased
  2. Arthralgia
  3. Blood potassium decreased
  4. Death
  5. Fatigue
  6. Hypotension
  7. Memory impairment
  8. Pain
  9. Pyrexia
  10. Respiratory tract infection

60+:

  1. Pulmonary embolism
  2. Cardiac failure congestive
  3. Hypervolaemia
  4. Oedema peripheral
  5. Pneumonia
  6. Renal impairment
  7. Urinary retention
  8. Urinary tract infection
  9. White blood cell count increased

Common conditions people have *:

  1. Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 7 people, 70.00%
  2. Haemochromatosis (body to absorb more iron than usual from food): 3 people, 30.00%
  3. Anaemia (lack of blood): 3 people, 30.00%

* Approximation only. Some reports may have incomplete information.

Do you take Folic acid and Reblozyl?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Folic acid and Reblozyl:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Folic acid side effects:

Browse all side effects of Folic acid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Folic acid interactions:

Browse all interactions between Folic acid and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on folic acid and luspatercept-aamt (the active ingredients of Folic acid and Reblozyl, respectively), and Folic acid and Reblozyl (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Folic acid and Reblozyl.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: